Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
290.08 USD   -0.63%
01/27Disappointing Tech Earnings, Outlook Weigh on Exchange-Traded Funds, Equity Futures Pre-Bell
MT
01/27Biogen, Eisai Say European Medicines Agency Accepts for Review Regulatory Application for Alzheimer's Disease Drug
MT
01/26Biogen Alzheimer's Drug Lecanemab Gets EU Marketing Authorization
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

China COVID-19 Protests Weigh on US Equities as Sentiment Sours Amid Growth Worries

11/28/2022 | 01:07pm EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ADOBE INC. 1.34% 370.71 Delayed Quote.8.70%
BIOGEN INC. -0.63% 290.08 Delayed Quote.4.75%
DOW JONES INDUSTRIAL 0.08% 33978.08 Real-time Quote.2.51%
NASDAQ COMPOSITE 0.95% 11621.71 Real-time Quote.11.04%
SHANGHAI A INDEX 0.76% 3422.19 Real-time Quote.5.68%
SHANGHAI STOCK EXCHANGE B SHARES INDEX 0.72% 300.1908 Real-time Quote.6.46%
SILVER 0.11% 23.587 Delayed Quote.-0.19%
All news about BIOGEN INC.
01/27Disappointing Tech Earnings, Outlook Weigh on Exchange-Traded Funds, Equity Futures Pre..
MT
01/27Biogen, Eisai Say European Medicines Agency Accepts for Review Regulatory Application f..
MT
01/26Biogen Alzheimer's Drug Lecanemab Gets EU Marketing Authorization
DJ
01/26Marketing authorization application for lecanemab as treatment for early alzheimer's di..
PR
01/26Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Di..
GL
01/26Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Di..
AQ
01/26Eisai Co., Ltd. and Biogen Inc. Announce European Medicines Agency Accepts Marketing Au..
CI
01/25Lonza underscores growth prospects with share buy-back, dividend hike
RE
01/24Biogen : Shares Update on FDA Advisory Committee Meeting for Tofersen
PU
01/24Morgan Stanley Adjusts Price Target on Biogen to $345 From $325, Maintains Overweight R..
MT
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2022 10 068 M - -
Net income 2022 2 873 M - -
Net Debt 2022 266 M - -
P/E ratio 2022 14,3x
Yield 2022 -
Capitalization 41 772 M 41 772 M -
EV / Sales 2022 4,18x
EV / Sales 2023 4,11x
Nbr of Employees 9 610
Free-Float 85,2%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Last Close Price 290,08 $
Average target price 322,44 $
Spread / Average Target 11,2%
EPS Revisions
Managers and Directors
Christopher A. Viehbacher President, Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP
Sector and Competitors